Prednisone raw material characterization and formulation development
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Pharmaceutical Sciences |
Texto Completo: | https://www.revistas.usp.br/bjps/article/view/142563 |
Resumo: | Solid dosage forms for oral use, particularly tablets, are the most highly used dosage forms in therapy because they are easily administered, have high productivity and relatively low cost and provide a more stable drug to form a semi-solid net. Numerous parameters influence the quality of the final dosage form. In this study, the dissolution profile of 20-mg prednisone tablets bioequivalent to the reference product and three test formulations were evaluated using stability testing. During the study, prednisone tablets and the active pharmaceutical ingredient (API) prednisone from two different manufacturers were characterized with respect to their physical and physicochemical properties. The results showed that the dissolution profiles of the test batches and the reference product did not retain pharmaceutical equivalence throughout all the stability study. Notably, both samples of API prednisone were of the same crystal form, and any phase transition that occurred during the study could not be attributed to dissolution variation during stability. |
id |
USP-31_8974c7f2918696d1071a42a5e4b8bcbd |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/142563 |
network_acronym_str |
USP-31 |
network_name_str |
Brazilian Journal of Pharmaceutical Sciences |
repository_id_str |
|
spelling |
Prednisone raw material characterization and formulation developmentPrednisone/tablets/dissolutionSolubilityFormulationStability Solid dosage forms for oral use, particularly tablets, are the most highly used dosage forms in therapy because they are easily administered, have high productivity and relatively low cost and provide a more stable drug to form a semi-solid net. Numerous parameters influence the quality of the final dosage form. In this study, the dissolution profile of 20-mg prednisone tablets bioequivalent to the reference product and three test formulations were evaluated using stability testing. During the study, prednisone tablets and the active pharmaceutical ingredient (API) prednisone from two different manufacturers were characterized with respect to their physical and physicochemical properties. The results showed that the dissolution profiles of the test batches and the reference product did not retain pharmaceutical equivalence throughout all the stability study. Notably, both samples of API prednisone were of the same crystal form, and any phase transition that occurred during the study could not be attributed to dissolution variation during stability.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2017-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/14256310.1590/s2175-97902017000400088Brazilian Journal of Pharmaceutical Sciences; Vol. 53 Núm. 4 (2017); e00088Brazilian Journal of Pharmaceutical Sciences; v. 53 n. 4 (2017); e00088Brazilian Journal of Pharmaceutical Sciences; Vol. 53 No. 4 (2017); e000882175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/142563/137596Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)info:eu-repo/semantics/openAccessToehwé, Leonardo HenriquePrado, Livia DerisRocha, Helvécio Vinícius Antunes2018-03-05T19:53:58Zoai:revistas.usp.br:article/142563Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2018-03-05T19:53:58Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Prednisone raw material characterization and formulation development |
title |
Prednisone raw material characterization and formulation development |
spellingShingle |
Prednisone raw material characterization and formulation development Toehwé, Leonardo Henrique Prednisone/tablets/dissolution Solubility Formulation Stability |
title_short |
Prednisone raw material characterization and formulation development |
title_full |
Prednisone raw material characterization and formulation development |
title_fullStr |
Prednisone raw material characterization and formulation development |
title_full_unstemmed |
Prednisone raw material characterization and formulation development |
title_sort |
Prednisone raw material characterization and formulation development |
author |
Toehwé, Leonardo Henrique |
author_facet |
Toehwé, Leonardo Henrique Prado, Livia Deris Rocha, Helvécio Vinícius Antunes |
author_role |
author |
author2 |
Prado, Livia Deris Rocha, Helvécio Vinícius Antunes |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Toehwé, Leonardo Henrique Prado, Livia Deris Rocha, Helvécio Vinícius Antunes |
dc.subject.por.fl_str_mv |
Prednisone/tablets/dissolution Solubility Formulation Stability |
topic |
Prednisone/tablets/dissolution Solubility Formulation Stability |
description |
Solid dosage forms for oral use, particularly tablets, are the most highly used dosage forms in therapy because they are easily administered, have high productivity and relatively low cost and provide a more stable drug to form a semi-solid net. Numerous parameters influence the quality of the final dosage form. In this study, the dissolution profile of 20-mg prednisone tablets bioequivalent to the reference product and three test formulations were evaluated using stability testing. During the study, prednisone tablets and the active pharmaceutical ingredient (API) prednisone from two different manufacturers were characterized with respect to their physical and physicochemical properties. The results showed that the dissolution profiles of the test batches and the reference product did not retain pharmaceutical equivalence throughout all the stability study. Notably, both samples of API prednisone were of the same crystal form, and any phase transition that occurred during the study could not be attributed to dissolution variation during stability. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/142563 10.1590/s2175-97902017000400088 |
url |
https://www.revistas.usp.br/bjps/article/view/142563 |
identifier_str_mv |
10.1590/s2175-97902017000400088 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/142563/137596 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso) info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso) |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
dc.source.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences; Vol. 53 Núm. 4 (2017); e00088 Brazilian Journal of Pharmaceutical Sciences; v. 53 n. 4 (2017); e00088 Brazilian Journal of Pharmaceutical Sciences; Vol. 53 No. 4 (2017); e00088 2175-9790 1984-8250 reponame:Brazilian Journal of Pharmaceutical Sciences instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Brazilian Journal of Pharmaceutical Sciences |
collection |
Brazilian Journal of Pharmaceutical Sciences |
repository.name.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
bjps@usp.br||elizabeth.igne@gmail.com |
_version_ |
1800222913311277056 |